King, Astellas Sue Teva Over Adenoscan Patent

Law360, New York (June 10, 2005, 12:00 AM EDT) -- King Pharmaceuticals and Astellas Pharmaceuticals have filed a lawsuit against Israeli generics maker Teva Pharmaceutical for infringing violating King's patent on pharmacologic stress agent Adenoscan.

Filed in the U.S. District Court for the District of Delaware, the lawsuit seeks a court order prohibiting the U.S. Food and Drug Administration’s approval of Teva subsidiary Sicor's abbreviated new drug application for a generic version of Adenoscan (adenosine injection) before the expiration of King's U.S. patent, Astellas said.

Adenoscan is used as an adjunct to thallium-201 myocardial perfusion scintigraphy...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.